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Abstract
Amyloid imaging has been approved for clinical use for measuring  amyloid plaque load in pa-
tients being evaluated for Alzheimer's disease or other causes of cognitive decline. Here we explore
a multidimensional approach to cognitive decline, where we situate amyloid plaque burden among
a number of other relevant dimensions, such as aging, volume loss, other proteinopathies such as
TDP43 and Lewy bodies, and functional reorganisation of cognitive brain systems. The multidi-
mensional model incorporates a 'pure AD' trajectory, corresponding to e.g. monogenic Alzheimer's
disease, but leaves room for other combinations of biomarker abnormalities (e.g. volume loss with-
out amyloid positivity) and other trajectories. More tools will become available in the future that
allow one to carve out a causal-mechanistic space for explaing cognitive decline in a personalized
manner, enhancing progress towards more ecacious interventions.
1 Introduction
Thanks to amyloid positron emission tomography (PET) it has become possible to measure in vivo
the neuritic plaque burden in an individual's brain [1, 2, 3, 4]. Very recently, large-scale prospective
longitudinal multimodal imaging datasets that incorporate amyloid imaging in hundreds of subjects
have started to illuminate fundamental questions about the pathophysiology of cognitive decline in
older adults, in a way that could not be imagined even 15 years ago. Longitudinal measurements
of amyloid load have also been applied to assess amyloid-lowering study drug interventions, which
unfortunately did not yield clinical benet [5, 6, 7]. Paradoxically, one of the most remarkable
discoveries based on amyloid imaging is the substantial portion of patients who have a clinical
phenotype of amnestic mild cognitive impairment (MCI) or even clinically probable Alzheimer's
disease (AD), but actually do not have an increased amyloid load [8, 9, 7, 10]. Until a few years
ago clinicians may have been relatively condent about the positive predictive value of their clinical
diagnoses of amnestic MCI or clinically probable AD for the presence of neuritic amyloid plaque,
nevertheless 10-40% of such cases actually do not have increased amyloid burden [8, 9, 11, 10, 12].
The clinical use of amyloid imaging has been approved by regulatory authorities for the purpose
of measuring  amyloid plaque load in patients under evaluation for AD. The distinction between
a disease-oriented (distinction AD from non-AD) and a process-oriented diagnostic tool (assess-
ment of amyloid load) is important: It reects a shift towards measurements of pathophysiological
processes in an individual, away from assigning cases to conventional disease categories. Without
doubt a categorical diagnostic approach is appropriate for a number of diseases encountered in a
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memory clinic, such as autosomal dominant AD, Huntington's disease, or syphilitic dementia, to
name just a few. In the current review however we will explore the merits of a multidimensional
approach [4]. The term 'multidimensional' refers to the traditional mathematical approach of mul-
tidimensional scaling, where a datapoint (a case) is plotted against a number of axes (dimensions).
Such a data-driven approach respects the heterogeneity between patients as well as the overlap
between seemingly distinct conventional clinical categories. According to this multidimensional
view, amyloid imaging is heralding a new era where we will be able to measure multiple relevant
pathophysiological dimensions in an individual on a personalized basis and tailor interventions ac-
cordingly.
A telling example for illustratory purposes is Lewy body dementia. In Lewy body dementia,
amyloid PET is often positive [13, 14]. Wihtin a multidimensional mindset, a logical approach
would be to apply multimodal imaging rather than to insist on assigning the case to a single
diagnostic category, either Lewy body dementia or AD [15]. Multimodal imaging of volume loss,
18F-uorodeoxyglucose (FDG) PET metabolism, dopaminergic integrity and amyloid PET in a
given individual enables a personalized approach to diagnosis and, hopefully, future interventions
[15]. Every day clinicians encounter many similar situations, e.g. instances where cerebrovascular
disease, cerebral amyloid angiopathy and AD overlap, or in the vast majority of elderly patients
with cognitive decline above the age of 80.
One of the principal arguments in favor of the multidimensional model comes from genetic
association studies in AD (for review see [16]) which implicate more than 30 polymorphisms pointing
to a dysregulation of a multiple molecular networks beside the APP processing pathway. These are
related to inammatory, lipid processing, and cell cycle pathways, among others [16]. The most
vulnerable nodes within these molecular networks are the hubs [16], one of which is the Amyloid
Precursor Protein (APP). The molecular hub-and-network approach may create favorable conditions
for developing more ecacious therapy, besides the amyloid-lowering strategy [7].
Population-based epidemiological studies point into the same direction. Although a strong
relationship exists between dementia and the presence of neurobrillary tangles and neuritic plaques
until 75 years of age [17], this relationship becomes weaker above the age of 80, especially for neuritic
plaques. In contrast, neuropathological measures of volume loss retain their strong relationship with
the presence or absence of dementia over the entire age range [17]. The causes of volume loss are
much broader than amyloid burden alone as will be discussed later in this review.
The purpose of the current review is to critically analyze the tripartite amyloid load, neurode-
generation and cognitive decline within a multidimensional framework. This multidimensional space
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encompasses the trajectory of what has been called 'pure' AD, as specied by the sequential model
triggered by amyloid proposed by Jack et al. (2013) [18]. It however also allows for combinations of
biomarker abnormalities that fall outside the boundaries of the sequential model (e.g. hippocampal
volume loss or episodic memory decline without amyloid positivity). As we will review, such com-
binations are frequent and we expect their frequency to increase as more tools become available to
measure causal dimensions beyond amyloid alone.
2 Sequential model with amyloid as a trigger
The tripartite between amyloid aggregation, neurodegeneration and cognitive decline is the center-
piece of one of the most inuential heuristic models of AD pathogenesis to date, the Jack et al.
(2013) [18] model. This model is a translation of the amyloid cascade hypothesis [19, 20] into a
sequence of changes that can be measured by contemporary techniques in vivo in humans. Its basic
tenets are
1. A number of measures are grouped under a common denominator called 'neurodegeneration'.
These measures include volume loss as measured with structural magnetic resonance imaging
(MRI), FDG PET hypometabolism, and cerebrospinal uid (CSF) total tau increase.
2. The panoply of in vivo measures evolve over time according to an orderly chronological se-
quence. The initial event is  amyloid related (as measured by means of amyloid PET and
CSF A42). This serves as a trigger for 'neurodegeneration' (e.g. hippocampal volume loss).
Positive markers of neurodegeneration are followed by and go along with clinical symptoms,
as has been demonstrated e.g. for volume loss by numerous studies [21, 22, 23, 17, 24, 25].
3. Changes over time of each of these measures are best described by sigmoidal curves. The
steepness of the slope for each measure can be considered as an indication of the phase of the
disease [26]. This time dimension can be expressed as years or on an 'Alzheimer's Disease
Progression Scale' [27]. For clinical drug trials, ideally, one would like to include subjects
when they are at a stage where the primary outcome measure is near the point of maximal
rate of change.
This sequential model has been successfully applied to population-based longitudinal multimodal
imaging datasets, such as the Mayo Clinic Study of Aging (MCSA) (n > 400, including cognitively
intact subjects as well as > 100 MCI cases) and the Baltimore Longitudinal Study of Aging (BLSA,
n > 800), and also to the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Australian
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Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL). The latter two studies have
recruited cognitively intact participants from the community combined with memory clinic recruited
patients with early or late MCI and early-to-moderate stage AD.
Modelling the sigmoidal changes for each of the measures on the basis of these large datasets has
yielded exciting novel insights. For instance, in BLSA the episodic memory measure which changed
rst in healthy older adults was the total learning score of the 15-word list recall test [27]. After a
period of time the delayed recall also started to decline. As subjects advanced to the clinical stage,
the rate of change in delayed recall became more prominent than the rate of change of the total
learning score [27]. Sigmoidal curves have also been applied to quantitative measures of neocortical
thinning, an established method for analyzing structural changes in neocortex. Cortical thinning
of AD vulnerable neocortical regions follows a sigmoidal curve, with the maximum speed at the
inection point around a MiniMental State Examination (MMSE) score of 21 out of 30 [24]. This
is consistent across all AD vulnerable regions [28]. In contrast, hippocampal volume continues to
decline (positive acceleration) until an MMSE of at least 15 out of 30 (lower limit in study) [24].
Among healthy controls and MCI patients, a higher baseline amyloid burden is associated with
a higher rate of amyloid accumulation over the following years [29, 30, 31, 32], regardless of the
baseline hippocampal volume [32]. Over time, amyloid positivity is associated with a higher rate
of subsequent volume loss, mainly in temporal neocortex and posterior cingulate [33], in particular
in cases who already have hippocampal volume loss to start with [32]. When patients have evolved
into the probable AD stage, amyloid retention values are at a plateau with almost no subsequent
change [31]. In the AIBL study, the timespan from a clearly negative amyloid PET to a manifestly
positive, AD-like PET was estimated to be no less than 30 years [31].
The most powerful tests of the sequential model have come from longitudinal studies in subjects
with autosomal dominant AD [34, 35, 36]. According to a large-scale international study of carriers
of AD genetic mutations [34], amyloid deposition in precuneus occurs 28 years before symptom
onset, hippocampal volume loss at about -15 years and glucose hypometabolism in precuneus at
around -18 yrs. In another monogenic AD cohort, the Presenilin 1 (PS1) E280A mutation kindred
(also called the Antioquia (Columbia) kindred), MCI starts on average at the age of 44 and AD
at the age of 49 years [35, 36]. Fibrillar A (as measured with 18F-orbetapir PET) begins to
accumulate in mutation carriers at a mean age of 28 years, rises steeply over the next 9 years and
plateaus at a mean age of 38 years, about 6 and 11 years before the expected MCI and dementia
onset. Surprisingly, in presymptomatic monogenic AD A42 initially increases before it drops to
a level below that seen in normal controls at around -20 yrs [34, 36, 37]. The initial A42 rise is
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surprising as prior to these studies the only pathological values described for A42 were decreases
compared to controls.
The sequential model captures the sequence and nature of changes that are strictly Alzheimer
related, and optimally ts the disease course in monogenetic cases. However, a number of common
pathophysiological processes are left out and underspecied in the sequential model of AD-related
changes. These are the 'confounding problem of non-AD pathophysiologies in elderly cohorts' [18].
Likewise, the neuropathological basis of the measures subsumed under the term 'neurodegeneration'
is complex. Several pathological processes converge on the same brain structures that mediate
cognitive decline [22, 25]. While cross-sectional [38] and longitudinal [23] measures of MRI volume
loss correlate with neurobrillary tangles and neuritic plaque load, MRI volume reects more than
neuronal loss caused by AD pathology alone. It is also aected by aging, vascular changes or
hippocampal sclerosis and many other factors [39, 40, 22, 25]. This is relevant for trial design: while
selective neuronal loss would be an exquisite drug target, multicomposite measures such as MRI,
FDG PET or CSF tau may have limited utility as these measures are the integral outcome of a
wide variety of processes.
3 A cellular denition of neurodegeneration
Neurodegeneration refers to regionally selective neuronal loss, preceded by early neuronal dysfunc-
tion and synaptic loss. Its key feature is the selectivity for specic types of neurons in specic
regions of the brain [41, 42, 43, 44]. Neuronal loss (neurodegeneration in its strict denition) is
directly related to cognitive decline [45, 46, 41, 47, 48]. For that reason, neuronal loss is a process
that one would denitely want to intervene against. If we could preserve neurons, clinical outcome
measures would most likely be favorably aected.
Neurodegeneration is associated with the aggregation of proteins in extra- or intracellular space
[49]. In AD, this consists not only of neuritic amyloid plaques and neurobrillary tangles. Tar
DNA Binding Protein (TDP)-43 proteinopathy, for instance, occurs in 50% of AD causes and is
more extensive in AD than previously thought [40]. It is associated with cognitive impairment
in multiple domains and can result in a phenotype that closely resembles that seen in AD [40].
Prospective community-based neuropathological studies have also highlighted the contribution of
cerebrovascular lesions [50] or Lewy bodies [51] to cognitive decline in AD. According to the Vienna
Transdube Aging study, the dierent proteinopathies make partly independent contributions to
cognitive decline [52, 49]. Dierent combinations of proteinopathies may have a cumulative eect
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until a threshold for cognitive dysfunction is exceeded and mechanisms of compensation fail [52].
One of the fundamental questions in the pathogenesis of neurodegenerative diseases is the re-
lationship between selective neuronal loss and the intra- and extracellular proteinopathy. In AD,
how does amyloid aggregation relate to selective neuronal loss? Does it cause neuronal loss or is it,
like neuronal loss, a consequence of a third-party cause? Proteinopathies may also be markers of
diseases that involve complex cascades of events that over time result in cognitive decline and/or
dementia [16, 53].
Recent longitudinal neuropathological studies in large population-based cohorts have yielded
critical insights into the relationship between brain volume loss, proteinopathies and cognitive de-
cline that often go against commonly held views [17, 53, 40]. In a large-scale prospective population-
based clinicopathological study, the Rush Memory and Aging study combined with the Religious
Order studies [40, 53], AD pathologic indices explained 30 to 34% of the between-subjects variance,
infarcts 1 to 3%, neocortical Lewy bodies 4 to 8%, and locus coeruleus noradrenergic neuronal
density 3-6% of variance. In other words, approximately 60% of the variance in late-life cognitive
decline remained unexplained by the classical neuropathological markers. The authors refer to this
unexplained variance as the 'pathology-cognition gap' [53]. There have been endeavours by neu-
ropathologists to try to measure compensatory mechanisms postmortem [53, 54]. In vivo measures
however, as provided by functional MRI, may be even more appropriate as a method to bridge the
pathology-cognition gap.
4 In vivo measures beyond what can be measured post
mortem: Brain circuits at work (and 'at rest')
Structural or biochemical measures post mortem fall inherently short of capturing the rich dimen-
sions of the functioning brain during life at a systems level. Functional MRI has revealed a number
of important and novel insights in how cognitive brain systems at work react to amyloid-related
injury and how functional connectivity drives regional vulnerability for amyloid aggregation.
4.1 Evidence of functional compensation from task-related fMRI
Among the most popular episodic memory tasks for fMRI is face-name associative learning. Sub-
jects have to encode and subsequently retrieve a list of pairs of a face and a name. This task
activates the hippocampal formation in normal controls. A series of fMRI studies have evaluated
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how hippocampal activity levels change over the course of AD: During the initial AD phase fMRI
responses are higher than in normal controls, suggestive of compensatory mechanisms [55]. As the
disease progresses, this pattern is reversed so that at the late MCI and early clinically probable AD
stage fMRI activity levels in the same region are lower than in normal controls [55]. This sequence
was also conrmed by a PS1 E280A mutation study [56, 36]: Hippocampal and parahippocampal
responses are higher in presymptomatic mutation carriers aged between 18 and 30 years than in
controls and precuneus is less deactivated [56, 36]. A similar sequence may occur in APOE 4
carriers in the pre- or post-amyloid phase [57].
Adaptive mechanisms in AD have also been demonstrated using fMRI in the language domain
[58, 59]. In MCI and early-stage AD, activity during associative-semantic processing in the left
posterior superior temporal sulcus, a key region for lexical-semantic retrieval, is lower than in
healthy controls [58, 59]. Response amplitude correlates with scores on confrontation naming and
with speed of identication of written words. In the homotopical right-sided region, activity is higher
in those AD subjects in whom confrontation naming is preserved compared to controls, suggestive
of compensatory mechanisms [59].
In a third cognitive domain, executive functions, mainly prefrontal increases have been described
[60, 61].
4.2 Intrinsic connectivity as a determinant of regional AD vulnerability
In vivo amyloid imaging has revealed the areas of predilection for amyloid aggregation in the earliest
disease phase. These areas are precuneus, orbitofrontal cortex and anterior cingulate [62, 63, 64,
65, 66]. Intrinsic connectivity network analysis (ICN) [67, 68, 69, 70] has shed light on one of
the most fundamental questions in neurodegenerative disease, the determinants of this regional
vulnerability. Originally, the emphasis was on the concordance between one of the ICNs, the default
mode network, and amyloid deposition [68]. However, amyloid deposition extends beyond DMN,
even in the earliest stages of AD [57, 71]. More recently, the focus has shifted to determining which
nodes within networks are most aected and why. A node's vulnerability is best predicted by a
greater total connectional ow through that node and by a shorter functional path to the disease-
related epicenters [70, 71]. Regional specicity of amyloid deposition therefore does not only depend
on which network but also on the hub status of nodes within those networks [57]. Apart from its
hub status, a high aerobic glycolysis index may also predispose to selective vulnerability [72].
Vandenberghe R, Current Neurology and Neuroscience Reports, 14, 498, 1-9, 2014 9
5 Temporal ordering of in vivo imaging measures prior to
clinical manifestations
A positive amyloid PET scan in a subject who does not show any cognitive decits is a frequent
occurrence, in particular with increasing age, rising from 5% between 50 and 60 years of age up to
50% above the age of 82 [73, 66, 74]. This asymptomatic stage [54] is referred to as the 'at risk of
AD' stage by the International Working Group-2 [75], which reserve the term 'presymptomatic'
for asymptomatic carriers of fully penetrant mutations. Theoretically, a distinction should be
drawn between risk factors for cognitive decline, on the one hand, and biomarkers that reveal
pathological changes before the disease becomes clinically manifest, on the other hand. For instance,
APOE4 carrier status is a risk factor and increases the risk of AD, in particular in women [76].
APOE4 is also robustly associated with a higher risk of a positive amyloid scan in healthy controls
[77, 31, 73, 66]. Other genetic polymorphisms, e.g. related to CR1 or Brain Derived Neurotrophic
Factor (BDNF) codon 66 may also aect the amyloid burden according to preliminary evidence
from case-control studies in smaller groups of subjects [78, 65].
The National Institute for Aging-Alzheimer Association (NIA-AA) nomenclature has introduced
the term of preclinical AD [79], which implies that if a subject with preclinical AD lives long enough,
he will develop clinical AD. The sequential order of biomarker positivity as specied by Jack et al.
[18] has laid the foundation for the NIA-AA criteria for preclinical AD [79]: Stage 0 corresponds to
cases with normal cognition, normal amyloid load and normal hippocampal volume, stage 1 to cases
with amyloid positivity, stage 2 to cases with amyloid positivity and hippocampal volume loss, and
stage 3 to cases with subtle cognitive changes, amyloid positivity and hippocampal volume loss.
Soon after this NIA-AA preclinical AD research staging was proposed, it was clear that the
combinations of amyloid and structural MRI ndings seen in reality on a relatively frequent basis
did not conform to the predictions based on the sequential model [18]. According to a support
vector machine analysis of the phase 2 18F-utemetamol study, structural MRI scans show more
often an AD-like pattern in cognitively intact controls than amyloid scans do [80]. In an MCSA
series of 286 cognitively intact healthy controls, more than half showed imaging abnormalities, with
the largest group (n = 69) showing hippocampal volume loss while being amyloid negative [81], a
phenomenon dubbed 'suspected non-Alzheimer Pathophysiology' (sNAP). The sNAP group does
not dier in any other respect from the preclinical AD cases in stage 2 or 3, e.g. in terms of regional
brain volume loss or FDG PET regional hypometabolism [82]. In other words, they are classied
as non-AD because of the absence of amyloid-positivity but are otherwise not distinguishable from
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the preclinical AD cases.
In amyloid-positive cognitively intact subjects, studies of cortical thinning yields a rather dier-
ent picture from hippocampal volumetry. At a time when hippocampal volume is still within the
normal range, amyloid positivity in healthy controls is associated with cortical thinning in posterior
cingulate/precuneus, inferior parietal, rostral middle frontal, and superior temporal cortex [24, 83].
Early structural changes in neocortex which precede changes of the hippocampal formation were
also reported in the PS1 E280A kindred: Parietal volume was lower in the carriers even before
amyloid load increased, similarly to what had been previously described in APOE 4 carriers [36].
Amyloid-positivity in cognitively intact controls is also associated with a disruption of intrinsic
connectivity between the precuneus and a large number of other regions [84].
6 Amyloid load and the path towards cognitive decline
sNAP subjects are as likely to progress within one year as subjects in NIA-AA preclinical AD stage 1
(10%) and more likely than subjects in phase 0 (5%). If subjects are both amyloid-positive and have
hippocampal atrophy (stage 2), they are more likely to progress than subjects who have either of the
two abnormalities (21%) [85]. Genetic risk factors beyond APOE may also aect the risk of cognitive
decline in amyloid-positive cognitively intact subjects. Among amyloid-positive subjects, BDNF
codon 66 met carriers experience faster cognitive decline (episodic memory, executive function,
language) over 36 months period [86].
The prevalence of a positive amyloid scan in MCI is approximately 50-70% [8, 87, 10]. Amyloid-
positive subjects with MCI are much more likely to progress to dementia within 20-24 months than
amyloid-negative subjects (50-67% versus 5-19%) [88, 89, 9, 90, 87]. Among amyloid positive sub-
jects with MCI, hippocampal atrophy predicts shorter time-to-progression while A load does not
[88]. In contrast, when amyloid-positive and amyloid-negative subjects with MCI are combined, hip-
pocampal atrophy and A load predict shorter time-to-progression with comparable power (hazard
ratio for an inter-quartile dierence of 2.6 for both) [88].
Among patients with MCI, a signicant portion (15-30%) have pathological hippocampal vol-
umes with normal amyloid levels [91, 10], called MCI-sNAP [10]. These patients are also at risk for
progression, and, according to at least one study involving MCSA and ADNI cases, more so than
amyloid-positive MCI cases who have normal hippocampal volumes [10]. Similarly to the progres-
sion rates seen in sNAP, the rate of cognitive decline in MCI-sNAP suggest that there are other
pathways to cognitive decline than the amyloid-triggered pathway and that these pathways occur
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with a relatively high prevalence.
7 Conclusion
Amyloid positivity is by denition and convention considered a necessary condition for classifying
a case as AD. Cases who do not follow the course specied by the sequential model are assigned
to a non-AD category [92]. The time course of the MRI volume changes are represented in the
sequential model only in so far that the MRI volume changes are due to amyloid aggregation [92].
Other changes aect the brain e.g. due to aging, vascular factors, other proteinopathies... Hence
the occurrence of MRI changes in the absence of amyloid-positivity, which may sometimes resemble
the MRI pattern seen in AD (sNAP and MCI-sNAP). The proportion of patients with an amnestic
MCI or a clinically probable AD phenotype who are amyloid-negative was clearly under-estimated
prior to the advent of amyloid imaging. This highlights the importance of non-amyloid triggered
pathways to cognitive decline in the general population as well as in clinical practice.
The multidimensional model is complementary to the sequential model and attempts to acco-
modate the diversity of processes and trajectories that can be seen in older adults, without a priori
restriction to a conventional category of 'pure AD'. Importantly, the multidimensional model is not
meant as an alternative or a criticism of the sequential model but incorporates the trajectories as
specied by [18]. Evidently, despite the huge progress enabled by amyloid imaging, our ability to
measure relevant pathophysiological processes in vivo in humans is still in its infancy. As more tools
become available to carve out the causal-mechanistic space of cognitive decline in vivo in individual
cases, we expect a still wider variety of combinations that cross the boundaries between conventional
disease categories.
Regardless of which model one prefers, the primary goal is to identify druggable targets in
individuals. The multidimensional model builds on the molecular hub-and-network approach to
AD [16]. Starting from a descriptive level, it will hopefully pave the way for intervention in a
personalized manner which is broader than using amyloid-lowering treatment on its own.
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